Navigation Links
Vaginal Microbicides Might Help More Men Than Women

Researchers say clinical trials' design may also mask risk of HIV drug resistance

THURSDAY, July 10 ( HealthDay News) -- A new study questions whether vaginal microbicides being developed to help protect women against HIV infection could lead to new drug resistance from the virus that causes AIDS.

The study, published July 7 in the online issue of Proceedings of the National Academy of Sciences, also shows that, under certain circumstances, men may actually benefit a bit more than women from the microbicides, which are compounds that can be applied inside the vagina.

Drug companies are running clinical trials on some second-generation microbicides based on antiretroviral, or ARV, medicines.

The study by the UCLA AIDS Institute also questions the designs of these trials. The researchers made the conclusions by using mathematical models that simulate clinical trials and population-level transmission of HIV.

Under the scenarios the researchers developed, men were slightly more protected than woman in certain situations. This occurred when the in-trial microbicide, an ARV drug called dapivirine, was only effective about half the time in women -- a situation that could occur if HIV-positive women on microbicides developed drug-resistant strains of HIV that were then less likely to be transmitted to men.

"The antiretroviral drugs within these microbicides are the same as those used to treat people who are infected with HIV, so there is great expectation that these microbicides will be very effective," said first author Dr. David Wilson, of the National Centre in HIV Epidemiology and Clinical Research at Australia's University of New South Wales, in a prepared statement.

"But the concern is that these microbicides are going to lead to drug resistance," he said.

Concerns about drug resistance come from the fact that the current clinical trial drops women from the study if they turn up HIV-positive during monthly screening, the researchers said.

"Since monthly testing will take place in the dapivirine trial, we predict that few, if any, cases of acquired resistance will arise during the trial, even if the drug is readily absorbed (i.e., the microbicide is high risk)," the researchers wrote. "Therefore, our analyses have shown that high-risk microbicides could pass Phase III trials, as their potential to cause resistance will be masked by frequent testing."

More information

The U.S. Department of Health & Human Services has more about HIV prevention drugs.

-- Kevin McKeever

SOURCE: University of California, Los Angeles, news release, July 7, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
2. Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors
3. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
4. Antiretroviral Drugs May Prevent Vaginal Transmission of HIV
5. Vaginal progesterone gel may improve infant outcomes and...
6. Researchers develop new tool to predict who will use microbicides
7. ADHD Might Raise Kids Obesity Risk
8. Meditation, Yoga Might Switch Off Stress Genes
9. Could new discovery about a shape-shifting protein lead to a mighty morpheein bacteria fighter?
10. Stem Cells Might Treat Tough Fractures
11. Diabetes Might Help Spur Hearing Loss
Post Your Comments:
Related Image:
Vaginal Microbicides Might Help More Men Than Women
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology: